FDA grants Brukinsa accelerated approval in relapsed or refractory marginal zone lymphoma – BeiGene

BeiGene, Ltd. announced that Brukinsa (zanubrutinib) has received accelerated approval from the FDA for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.This accelerated approval is based on overall response rate (ORR). Continued approval for this indication may be contingent upon verification and description of clinical benefit […]